en · de · es · pt
semax-notes.peptides7501.com › Info › Semax Origin And Molecular Structure — Hands-On Walkthrough

Semax Origin And Molecular Structure — Hands-On Walkthrough

By Editorial Desk · published 2025-10-29 · last reviewed 2025-12-03 · Info

反相色谱 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-12-03. Anything still debated is marked as such rather than presented as settled.

Semax Origin and Molecular Structure

The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.

Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.

Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.

化学性质与分析表征

从分子层面看,Semax 是线性七肽,没有二硫键、糖基或脂链修饰,N 端为游离氨基,C 端为游离羧基。分子含组氨酸与谷氨酸侧链,因此在水和甲醇等极性溶剂中溶解良好,在非极性溶剂中溶解有限。计算分子量约为 814 Da,与其质子化离子的质荷比吻合,可用于质谱确认。

稳定性主要由水解与氧化两条路径支配。肽键在中性或弱酸性条件下相对稳定,遇到强碱或长时间高温则明显断裂;甲硫氨酸侧链容易被氧化成亚砜,使主峰前移并拉低实际含量。金属离子、光照和反复冻融会进一步促进降解或聚集。冻干粉在低温避光条件下可存放较长时间,配制后的水溶液通常需要冷藏并尽快用完。

Semax at a glance

PropertyValueNotes
Molecular formulaC37H51N9O10SFree acid form of the heptapeptide; depends on terminal groups
Molecular massAbout 813.9 g/molAverage mass used for mass spectrometry confirmation
AppearanceWhite to off-white solidSupplied as a lyophilised powder; hygroscopic
Solubility classFreely soluble in aqueous mediaWater, saline, and phosphate buffers; limited organic solubility
Typical storage temperature-20 degrees CelsiusLong term and dry; short working periods may use 2 to 8 degrees Celsius

Background and Development History

Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.

The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.

Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.

Related pages on this site

Analytical Methods and Stability Profile

Identity and purity of Semax are established mainly by reversed-phase high-performance liquid chromatography coupled with mass spectrometry. The chromatographic trace gives a purity estimate as a percentage of total peak area, while electrospray or matrix-assisted laser desorption ionization confirms the molecular mass against the calculated value. Amino acid analysis and sequence-specific fragmentation provide further confirmation when a supplier's chain of custody is unclear. Vendors frequently quote a purity figure without stating the detection wavelength or the integration method, which limits how far one number can be compared with another.

Stability depends heavily on physical state. Lyophilized powder held dry, cold and dark retains its content over long periods, whereas dissolved peptide begins to change within days at room temperature. The most cited degradation route is oxidation of the methionine residue, which converts the peptide to a sulfoxide form that elutes differently on chromatography. Hydrolysis of amide bonds and adsorption onto container walls contribute smaller losses. Buffers that exclude oxygen from the headspace slow the oxidation pathway, but no single condition prevents all change indefinitely.

Semax Structure and Research Background

Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.

Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.

Handling, Stability, and Quality Control

Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.

Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.

Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.

Supporting material

== Therapeutic approaches and pharmacology == Therapeutic approaches for IRAP regulation rely on the development of peptidomimetics and small molecule inhibitors. The most explored classes of inhibitors for IRAP are the catalytic or the allosteric site ones.

=== Food quality === The level of reducing sugars in wine, juice, and sugarcane are indicative of the quality of these food products, and monitoring the levels of reducing sugars during food production has improved market quality. The conventional method for doing so is the Lane-Eynon method, which involves titrating the reducing sugar with copper(II) in Fehling's solution in the presence of methylene blue, a common redox indicator. However, it is inaccurate, expensive, and sensitive to impurities.

==== Desert lung disease ==== A non-occupational form of silicosis, desert lung disease, is caused by long-term exposure to sand dust in desert areas, with cases reported from the Sahara, Libyan desert and the Negev. The disease is caused by deposition of sand dust in the lungs. Desert lung disease may be related to Al Eskan disease, a lung disorder thought to be caused by exposure to sand dust containing organic antigens, first diagnosed after the Gulf War. The relative importance of the silica particles and the microorganisms that they carry in health effects remains unclear.

Sources: en.wikipedia.org

Notes from published material

=== August === 3 August – Researchers propose a theoretical method using quantum lattice gates to perform operations on bosonic quantum error-correcting codes within a single driving cycle, potentially making some operations more than 1,000 times faster than previous approaches and advancing efforts towards fault-tolerant quantum computing. 5 August – A study published in the JAMA Network Open shows that the fecal immunochemical test (FIT) has reduced deaths from colorectal cancer. 13 August – A meta-analysis of more than 480,000 participants finds that regular stair climbing is associated with a 39% lower risk of cardiovascular mortality and a 24% lower risk of death from any cause. 17 August A team of researchers combine synthetic DNA and a semiconductor to produce an ultra-low-power memory device – one that can carry out both the storage and processing of information within a single, unified location. This cutting-edge, bio-hybrid technology may in time contribute to far greater energy efficiency across AI systems and next-generation computers alike. Researchers at the Max Planck Institute for Marine Microbiology find that dozens of animal species carry enzymes capable of breaking down microbe-derived bioplastics known as PHAs, a long-standing talent once believed to belong exclusively to microorganisms.

The American Society for Clinical Pathology (ASCP), formerly known as the American Society of Clinical Pathologists, is a professional association based in Chicago, Illinois, encompassing 130,000 pathologists and laboratory professionals. Founded in 1922, the ASCP provides programs in education, certification and advocacy on behalf of patients, pathologists and lab professionals. In addition, the ASCP publishes numerous textbooks, newsletters and other manuals, and publishes two industry journals: American Journal of Clinical Pathology (AJCP) and LabMedicine. On August 10, 2026, Dr. Alexandra Brown, MD, FASCP, was named CEO.

=== High androgen levels === CPA is used as an antiandrogen to treat high androgen levels and associated symptoms such as masculinization due to conditions like polycystic ovary syndrome (PCOS) and congenital adrenal hyperplasia (CAH) in women. It is almost always combined with an estrogen, such as ethinylestradiol, when it is used in the treatment of PCOS in women.

Sources: en.wikipedia.org

Frequently asked questions

What is semax derived from?

It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.

Is semax an approved medicine outside Russia?

It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.

What is known about its mechanism?

Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.

用什么方法确认分子量?

电喷雾或基质辅助激光解吸电离质谱是常用手段,测得的质子化离子质荷比可换算为分子量。结果与理论值落在合理误差内,才支持结构一致的判断。

Network